
Please try another search
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treatment of acute myeloid leukaemia/colorectal cancer, acute myeloid cancer, blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.
Name | Age | Since | Title |
---|---|---|---|
Paul Edward-Alexander Hopper | 67 | 2020 | Founder & Executive Chairman |
Lesley Russell | 63 | 2020 | Non-Executive Director |
Phillip Allen Hains | 65 | 2020 | CFO, Joint Company Secretary & Director |
Eric Smith | - | 2021 | Member of Cellular Immunotherapy Scientific Advisory Board |
Michael R. Bishop | - | 2021 | Member of Cellular Immunotherapy Scientific Advisory Board |
Eric M. Sullivan | 45 | 2023 | Non-Executive Director |
Stanley Frankel | - | - | Member of Cellular Immunotherapy Scientific Advisory Board |
David G. Maloney | - | 2021 | Member of Cellular Immunotherapy Scientific Advisory Board |
H. Miles Prince | - | 2025 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review